ATRA Stock Price, Atara Biotherapeutics Quote, Chart

Market Summary

USD0.63+0.03

Delayedas of 17 May 2024, 12:02 pm

5.00%

ATRA Stock Price

View Fullscreen

ATRA RSI Chart

ATRA Valuation

Market Cap

72.2M

Price/Earnings (Trailing)

-0.31

Price/Sales (Trailing)

1.02

EV/EBITDA

-0.17

Price/Free Cashflow

-0.39

ATRA Price/Sales (Trailing)

ATRA Profitability

EBT Margin

-366.65%

Return on Equity

237.12%

Return on Assets

-141.04%

Free Cashflow Yield

-256.21%

ATRA Fundamentals

ATRA Revenue

Revenue (TTM)

63.6M

Rev. Growth (Yr)

4.5K%

Rev. Growth (Qtr)

85.5%

ATRA Earnings

Earnings (TTM)

-233.1M

Earnings Growth (Yr)

57.53%

Earnings Growth (Qtr)

47.47%

Breaking Down ATRA Revenue

52 Week Range

0.602.54

(Low)(High)

Last 7 days

9.1%

Last 30 days

-11.8%

Last 90 days

-22.1%

Trailing 12 Months

-70.9%

How does ATRA drawdown profile look like?

ATRA Financial Health

Current Ratio

0.59

ATRA Investor Care

Shares Dilution (1Y)

22.91%

Diluted EPS (TTM)

-2.13

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	0
2022	24.1M	71.8M	70.9M	63.6M
2021	4.2M	8.0M	13.2M	20.3M
2015	272.0K	412.0K	762.0K	0
2014	40.3K	68.5K	96.8K	125.0K
2013	0	0	0	12.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Atara Biotherapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 31, 2024	fust matthew k	acquired	-	-	150,000	-
Mar 31, 2024	roncarolo maria grazia	acquired	-	-	150,000	-
Mar 31, 2024	mallik ameet	acquired	-	-	150,000	-
Mar 31, 2024	heiden william k	acquired	-	-	150,000	-
Mar 31, 2024	gallagher carol giltner	acquired	-	-	150,000	-
Mar 04, 2024	hyllengren eric j	sold	-4,810	0.720219	-6,679	evp, cfo
Mar 04, 2024	touchon pascal	sold	-17,887	0.72	-24,844	president and ceo
Mar 04, 2024	henrich jill	sold	-2,792	0.72	-3,879	evp, global head ra & quality
Mar 04, 2024	nguyen anhco	sold	-7,737	0.72	-10,746	evp, chief sci. & tech officer
Mar 04, 2024	murugan amar	sold	-7,231	0.72	-10,044	evp, chief legal officer

Which funds bought or sold ATRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	JACOBS LEVY EQUITY MANAGEMENT, INC	sold off	-100	-400,490	-	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	3,379	4,470,090	4,566,920	-%
May 15, 2024	Checkpoint Capital L.P.	new	-	619,640	619,640	0.41%
May 15, 2024	Woodline Partners LP	new	-	1,231,710	1,231,710	0.01%
May 15, 2024	STATE STREET CORP	reduced	-10.6	299,661	1,727,400	-%
May 15, 2024	MORGAN STANLEY	reduced	-24.94	14,573	934,214	-%
May 15, 2024	HSBC HOLDINGS PLC	new	-	7,817	7,817	-%
May 15, 2024	Atom Investors LP	new	-	21,797	21,797	-%
May 15, 2024	DEUTSCHE BANK AG\	reduced	-5.29	5,508	25,084	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	reduced	-10.46	318,387	1,822,080	-%

Are Funds Buying or Selling ATRA?

Are funds buying ATRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATRA

No. of Funds

Unveiling Atara Biotherapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 18, 2024	citadel advisors llc	6.4%	6	SC 13G
Feb 14, 2024	maverick capital ltd	0%	0	SC 13G/A
Feb 14, 2024	redmile group, llc	9.9%	10,301,409	SC 13G/A
Feb 13, 2024	vanguard group inc	6.56%	6,686,043	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 06, 2024	goldman sachs group inc	0.6%	580,629	SC 13G/A
Jan 26, 2024	blackrock inc.	7.0%	7,087,213	SC 13G/A
Jan 22, 2024	state street corp	2.73%	2,784,200	SC 13G/A
Jan 09, 2024	baupost group llc/ma	0%	0	SC 13G/A
Dec 07, 2023	jpmorgan chase & co	2.1%	2,206,929	SC 13G/A

Recent SEC filings of Atara Biotherapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 16, 2024	144	Notice of Insider Sale Intent
May 10, 2024	DEFR14A	DEFR14A
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Atara Biotherapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Atara Biotherapeutics Inc News

Latest updates

Atara Biotherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4
Revenue	85.5%	27,357,000	14,747,500	2,138,000	957,000	589,000	221,000	4,459,000	51,579,000	7,314,000	7,548,000	5,370,000	3,870,000	3,552,000	380,000	163,000	153,000	66,000	30,000	23,000	6,000	4,500
Costs and Expenses	-8.7%	58,604,000	64,214,000	71,750,000	-	76,244,000	-	89,081,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	72,371,000	76,244,000	75,760,000	89,081,000	83,711,000	95,534,000	100,951,000	90,182,000	87,872,000	81,797,000	-	-	-	-	-	-	-	-
S&GA Expenses	-100.0%	-	11,454,000	12,247,000	13,335,000	13,872,000	13,245,000	18,924,000	18,813,000	20,571,000	21,817,000	19,849,000	19,397,000	17,738,000	-	-	-	-	-	-	-	-
R&D Expenses	-8.3%	45,506,000	49,600,000	56,888,000	56,141,000	62,156,000	62,515,000	70,157,000	64,898,000	74,963,000	79,134,000	70,333,000	68,475,000	64,059,000	-	-	-	-	-	-	-	-
EBITDA Margin	15.8%	-3.52	-4.18	-4.42	-4.66	-3.27	-3.50	-3.38	-3.34	-14.16	-16.26	-24.23	-38.78	-	-	-	-	-	-	-	-	-
Interest Expenses	-90.3%	114,000	1,176,000	1,395,000	1,378,000	1,336,000	117,000	123,000	129,000	4,000	7,000	7,000	8,000	10,000	-	-	-	-	-	-	-	-
Income Taxes	118.2%	24,000	11,000	-19,000	1,000	22,000	2,000	10,000	-	-	30,000	-	16,000	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	47.5%	-31,728,000	-60,439,000	-69,816,000	-71,107,000	-74,749,000	-74,570,000	-84,081,000	18,466,000	-88,105,000	-93,319,000	-84,664,000	-83,777,000	-78,335,000	-	-	-	-	-	-	-	-
EBT Margin	15.6%	-3.67	-4.34	-4.57	-4.79	-3.38	-3.59	-3.48	-3.45	-14.52	-16.72	-24.91	-39.89	-	-	-	-	-	-	-	-	-
Net Income	47.5%	-31,752,000	-60,450,000	-69,797,000	-71,108,000	-74,771,000	-74,572,000	-84,091,000	18,466,000	-88,105,000	-93,349,000	-84,664,000	-83,793,000	-78,335,000	-	-	-	-	-	-	-	-
Net Income Margin	15.6%	-3.67	-4.34	-4.57	-4.79	-3.38	-3.59	-3.48	-3.45	-14.52	-16.72	-24.91	-39.90	-	-	-	-	-	-	-	-	-
Free Cashflow	41.1%	-29,739,000	-50,450,000	-51,627,000	-53,295,000	-38,828,000	-56,917,000	-65,189,000	-65,383,000	-87,134,000	-36,735,000	-62,834,000	-63,638,000	-67,895,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.1%	165	166	189	246	302	376	368	436	397	468	450	457	530	588	406	428	300	343	365	274	325
Current Assets	4.5%	106	102	119	172	224	295	283	347	314	385	369	392	464	523	339	359	229	273	293	201	251
Cash Equivalents	36.3%	35.00	26.00	65.00	46.00	49.00	93.00	66.00	72.00	103	107	115	125	152	202	64.00	76.00	72.00	76.00	96.00	61.00	58.00
Inventory	65.7%	16.00	10.00	7.00	8.00	5.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-22.5%	3.00	4.00	5.00	5.00	6.00	6.00	7.00	8.00	9.00	54.00	53.00	51.00	51.00	51.00	52.00	54.00	54.00	54.00	56.00	57.00	58.00
Liabilities	-0.4%	264	265	240	239	237	250	181	179	173	189	140	125	131	126	52.00	47.00	47.00	52.00	46.00	42.00	41.00
Current Liabilities	27.0%	181	142	79.00	75.00	68.00	79.00	72.00	66.00	102	106	86.00	89.00	84.00	83.00	36.00	32.00	32.00	37.00	31.00	26.00	25.00
Shareholder's Equity	0.9%	-98.31	-99.23	-	7.00	65.00	127	187	257	224	280	310	332	399	462	354	381	253	291	318	232	284
Retained Earnings	-1.6%	-2,000	-1,969	-1,908	-1,838	-1,767	-1,693	-1,618	-1,534	-1,552	-1,464	-1,371	-1,286	-1,202	-1,124	-1,043	-968	-891	-817	-739	-667	-593
Additional Paid-In Capital	1.7%	1,903	1,870	1,858	1,847	1,834	1,822	1,809	1,794	1,779	1,745	1,681	1,618	1,602	1,587	1,397	1,349	1,144	1,109	1,058	900	877
Shares Outstanding	12.1%	119	106	102	101	97.00	96.00	102	102	101	92.00	92.00	92.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	162	-	-	-	715	-	-	-	1,150	-	-	-	907	-	-	-	761	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	41.3%	-29.61	-50.41	-51.35	-52.80	-38.43	-56.88	-65.06	-63.96	-84.53	-34.27	-58.98	-61.58	-65.70	-4.12	-52.96	-56.64	-67.04	-58.69	-52.15	-54.59	-70.20
Share Based Compensation	-15.4%	8.00	10.00	11.00	13.00	12.00	11.00	14.00	14.00	14.00	14.00	14.00	14.00	12.00	12.00	13.00	14.00	13.00	12.00	12.00	15.00	12.00
Cashflow From Investing	48.0%	15.00	10.00	70.00	49.00	-6.01	51.00	60.00	32.00	60.00	-24.32	1.00	32.00	13.00	-36.89	8.00	-130	39.00	1.00	-58.52	50.00	68.00
Cashflow From Financing	1496.6%	24.00	2.00	-0.21	0.00	0.00	32.00	-0.21	1.00	20.00	51.00	47.00	2.00	3.00	179	34.00	191	24.00	37.00	146	7.00	-1.93

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATRA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Commercialization revenue	$ 27,357	$ 884
License and collaboration revenue	0	342
Total revenue	27,357	1,226
Costs and operating expenses:
Cost of commercialization revenue	1,985	216
Research and development expenses	45,506	62,156
General and administrative expenses	11,113	13,872
Total costs and operating expenses	58,604	76,244
Loss from operations	(31,247)	(75,018)
Other income (expense), net:
Interest income	604	1,802
Interest expense	(1,153)	(1,336)
Other income (expense), net	68	(197)
Total other income (expense), net	(481)	269
Loss before provision for (benefit from) income taxes	(31,728)	(74,749)
Provision for (benefit from) income taxes	24	22
Net loss	(31,752)	(74,771)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities	149	830
Comprehensive loss	$ (31,603)	$ (73,941)
Basic loss per common share	$ (0.23)	$ (0.72)
Diluted loss per common share	$ (0.23)	$ (0.72)
Basic weighted-average shares outstanding	140,587	103,969
Diluted weighted-average shares outstanding	140,587	103,969

ATRA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,087	$ 25,841
Short-term investments	11,152	25,884
Restricted cash	146	146
Accounts receivable	35,834	34,108
Inventories	16,084	9,706
Other current assets	8,131	6,184
Total current assets	106,434	101,869
Property and equipment, net	2,989	3,856
Operating lease assets	51,981	54,935
Other assets	3,868	4,844
Total assets	165,272	165,504
Current liabilities:
Accounts payable	2,854	3,684
Accrued compensation	5,707	11,519
Accrued research and development expenses	15,928	17,364
Deferred revenue	123,154	77,833
Other current liabilities	33,047	31,826
Total current liabilities	180,690	142,226
Deferred revenue - long-term	719	37,562
Operating lease liabilities - long-term	42,197	45,693
Liability related to the sale of future revenues - long-term	35,573	34,623
Other long-term liabilities	4,401	4,631
Total liabilities	263,580	264,735
Commitments and contingencies (Note 8)
Stockholders' equity (deficit):
Common stock - $0.0001 par value, 500,000 shares authorized as of March 31, 2024 and December 31, 2023; 120,325 and 106,447 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	12	11
Additional paid-in capital	1,902,637	1,870,112
Accumulated other comprehensive (loss) income	(55)	(204)
Accumulated deficit	(2,000,902)	(1,969,150)
Total stockholders' equity (deficit)	(98,308)	(99,231)
Total liabilities and stockholders' equity (deficit)	$ 165,272	$ 165,504

About Atara Biotherapeutics Inc

Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.

CEO	Dr. Pascal Touchon D.V.M.
WEBSITE	atarabio.com
INDUSTRY	Biotechnology
EMPLOYEES	317

Atara Biotherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Atara Biotherapeutics Inc? What does ATRA stand for in stocks?

ATRA is the stock ticker symbol of Atara Biotherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Atara Biotherapeutics Inc (ATRA)?

As of Thu May 16 2024, market cap of Atara Biotherapeutics Inc is 72.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATRA stock?

You can check ATRA's fair value in chart for subscribers.

What is the fair value of ATRA stock?

You can check ATRA's fair value in chart for subscribers. The fair value of Atara Biotherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Atara Biotherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Atara Biotherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether ATRA is over valued or under valued. Whether Atara Biotherapeutics Inc is cheap or expensive depends on the assumptions which impact Atara Biotherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATRA.

What is Atara Biotherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ATRA's PE ratio (Price to Earnings) is -0.31 and Price to Sales (PS) ratio is 1.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATRA PE ratio will change depending on the future growth rate expectations of investors.